Evidence map›Paper›PMID 25634179›Full record

ArticleMedicine2015

Impact of coexisting pulmonary diseases on survival of patients with lung adenocarcinoma: a STROBE-compliant article.

Zhi-Hong Jian, Jing-Yang Huang, Pei-Chieh Ko, Shiou-Rung Jan, Oswald Ndi Nfor, Chia-Chi Lung, Wen-Yuan Ku, Chien-Chang Ho, Hui-Hsien Pan, Yung-Po Liaw

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhi-Hong JianFrom the Department of Public Health and Institute of Public Health (Z-HJ, J-YH, P-CK, S-RJ, ONN, C-CL, W-YK, Y-PL), Chung Shan Medical University; Department of Family and Community Medicine (C-CL, Y-PL), Chung Shan Medical University Hospital, Taichung City; Department of Physical Education (C-CH), Fu Jen Catholic University, New Taipei City; and Department of Pediatrics and School of Medicine (H-HP), Chung Shan Medical University, Taichung City, Taiwan.
Jing-Yang Huang
Pei-Chieh Ko
Shiou-Rung Jan
Oswald Ndi Nfor
Chia-Chi Lung
Wen-Yuan Ku
Chien-Chang Ho
Hui-Hsien Pan
Yung-Po Liaw
Bridge University · SS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma, chronic obstructive pulmonary disease (COPD), and pulmonary tuberculosis (TB) are common pulmonary diseases associated with lung cancer. Besides, smoking is more prevalent in Taiwanese men. This study evaluated gender disparities in coexisting pulmonary diseases on survival of patients with lung adenocarcinoma. Patients newly diagnosed with lung cancer between 2003 and 2008 were identified from Taiwan National Health Insurance Research Database. Cases with lung adenocarcinoma were further confirmed using the Cancer Registry Database and followed up until the end of 2010. Cox proportional hazard regression was used to calculate the hazard ratio (HR) of coexisting asthma, COPD, and/or TB to estimate all-cause mortality risk. During the study period, 13,399 cases of lung adenocarcinoma were identified. The HRs of adenocarcinoma in men and women were 1.20 (95% confidence interval [CI], 1.10-1.30) and 1.05 (95% CI, 0.95-1.16), respectively, for individuals with asthma, 1.32 (95% CI, 1.16-1.51) and 0.97 (95% CI, 0.89-1.05), respectively, for COPD, and 0.99 (95% CI, 0.93-1.06) and 1.06 (95% CI, 0.86-1.32), respectively, for individuals with TB. Specifically, among men with coexisting pulmonary diseases, the HRs were 1.63 (95% CI, 1.25-2.13), 1.31 (95% CI, 1.08-1.59), and 1.23 (95% CI, 1.11-1.36) for individuals with asthma + COPD + TB, asthma + COPD, and COPD + TB, respectively. However, there was no increase risk of mortality among women with coexisting pulmonary diseases. Coexisting pulmonary diseases are at an elevated risk of mortality among male patients with lung adenocarcinoma. Such patients deserve greater attention while undergoing cancer treatment.

Indexed as

AdenocarcinomaAdultAsthmaCohort StudiesFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRegistriesRetrospective StudiesSex FactorsTaiwan

Identifiers

PMID25634179
PMCPMC4602976
OpenAlexW1975595880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.